Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks
Status:
Withdrawn
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This study evaluates the non-inferiority of Cefaliv® compared to Neosaldina® in the treatment
of migraine attack in two hundred and sixteen adults of both sexes with age between eighteen
and sixty five years old. The first Half of participants will receive Cefaliv®, the other
half will receive Neosaldina®.